BTIG Maintains Buy on Alcon, Lowers Price Target to $74
BTIG analyst Ryan Zimmerman maintains Alcon (NYSE:ALC) with a Buy and lowers the price target from $82 to $74.
Stocks · News reference
Alcon Announces FDA Approval For BRYTLY Redness Relief Eye Drops, Expanding Over The Counter Eye Care Portfolio.
One drop works to significantly reduce redness, with results lasting up to 12 hours1Lasts up to 50% longer than Lumify1-2,*Expands Alcon's portfolio of consumer eye care solutions and will be available in major
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Barclays Initiates Coverage On Alcon with Equal-Weight Rating, Announces Price Target of $70
Barclays analyst Christopher Pasquale initiates coverage on Alcon (NYSE:ALC) with a Equal-Weight rating and announces Price Target of $70.
Needham Reiterates Buy on Alcon, Maintains $98 Price Target
Needham analyst David Saxon reiterates Alcon (NYSE:ALC) with a Buy and maintains $98 price target.